US 11324813
Indoleamine 2,3-dioxygenase based immunotherapy
granted A61KA61K2039/5158A61K2039/55566
Quick answer
US patent 11324813 (Indoleamine 2,3-dioxygenase based immunotherapy) held by IO Biotech ApS expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- IO Biotech ApS
- Grant date
- Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2039/5158, A61K2039/55566, A61K2039/572, A61K38/193